Cargando…

Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases

Cerebrovascular and neurodegenerative disorders affect one billion people around the world and result from a combination of genomic, epigenomic, metabolic, and environmental factors. Diagnosis at late stages of disease progression, limited knowledge of gene biomarkers and molecular mechanisms of the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teijido, Oscar, Cacabelos, Ramón
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213964/ https://www.ncbi.nlm.nih.gov/pubmed/30332838 http://dx.doi.org/10.3390/ijms19103199

Ejemplares similares

Pharmacogenetics of Vascular Risk Factors in Alzheimer’s Disease
por: Cacabelos, Ramón, et al.
Publicado: (2018)

Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
por: Teijido, Óscar, et al.
Publicado: (2017)

The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity
por: Ohnmacht, Alexander Joschua, et al.
Publicado: (2023)

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics
por: Cacabelos, Ramón
Publicado: (2017)

Personalized Management and Treatment of Alzheimer’s Disease
por: Cacabelos, Ramón, et al.
Publicado: (2022)

Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response
por: Siamoglou, Stavroula, et al.
Publicado: (2023)

Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
por: Carrera, Iván, et al.
Publicado: (2019)

Personalized Medicine of Alzheimer’s Disease
por: Cacabelos, Ramón, et al.
Publicado: (2014)

Epigenetics of Aging and Alzheimer’s Disease: Implications for Pharmacogenomics and Drug Response
por: Cacabelos, Ramón, et al.
Publicado: (2015)

Donepezil in Alzheimer’s disease: From conventional trials to pharmacogenetics
por: Cacabelos, Ramón
Publicado: (2007)

Novel Approaches for the Treatment of Alzheimer’s and Parkinson’s Disease
por: Van Bulck, Michiel, et al.
Publicado: (2019)

Influence of Pathogenic and Metabolic Genes on the Pharmacogenetics of Mood Disorders in Alzheimer’s Disease
por: Cacabelos, Ramón, et al.
Publicado: (2021)

Sirtuins in Alzheimer’s Disease: SIRT2-Related GenoPhenotypes and Implications for PharmacoEpiGenetics
por: Cacabelos, Ramón, et al.
Publicado: (2019)

Natural Products as the Potential to Improve Alzheimer’s and Parkinson’s Disease
por: Kim, Sung Wook, et al.
Publicado: (2023)

Resveratrol Derivatives as Potential Treatments for Alzheimer’s and Parkinson’s Disease
por: Arbo, Bruno Dutra, et al.
Publicado: (2020)

Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson’s and Alzheimer’s Disease
por: Keighron, Cameron Noah, et al.
Publicado: (2023)

Pharmacogenomics of Cognitive Dysfunction and Neuropsychiatric Disorders in Dementia
por: Cacabelos, Ramon
Publicado: (2020)

A Comparative Evaluation of a Novel Vaccine in APP/PS1 Mouse Models of Alzheimer's Disease
por: Carrera, Iván, et al.
Publicado: (2015)

Epigenetic Studies in the Male APP/BIN1/COPS5 Triple-Transgenic Mouse Model of Alzheimer’s Disease
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2022)

Neuroprotective Effect of Nosustrophine in a 3xTg Mouse Model of Alzheimer’s Disease
por: Carrera, Iván, et al.
Publicado: (2023)

Nosustrophine: An Epinutraceutical Bioproduct with Effects on DNA Methylation, Histone Acetylation and Sirtuin Expression in Alzheimer’s Disease
por: Martínez-Iglesias, Olaia, et al.
Publicado: (2022)

Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease
por: Kim, Namdoo, et al.
Publicado: (2020)

Induced Pluripotent Stem Cells for Treatment of Alzheimer’s and Parkinson’s Diseases
por: Yefroyev, David A, et al.
Publicado: (2022)

Potential Benefits of Nobiletin, A Citrus Flavonoid, against Alzheimer’s Disease and Parkinson’s Disease
por: Nakajima, Akira, et al.
Publicado: (2019)

Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice
por: Carrera, Iván, et al.
Publicado: (2012)

Untangling the Tauopathy for Alzheimer’s disease and parkinsonism
por: Chang, Hui-Yun, et al.
Publicado: (2018)

Novel Insight into Functions of Transcription Factor EB (TFEB) in Alzheimer’s Disease and Parkinson’s Disease
por: Yang, Jing, et al.
Publicado: (2023)

Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease
por: Hoekstra, Jake G, et al.
Publicado: (2011)

Incretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
por: Nowell, Joseph, et al.
Publicado: (2022)

A Novel Treatment Strategy by Natural Products in NLRP3 Inflammasome-Mediated Neuroinflammation in Alzheimer’s and Parkinson’s Disease
por: Lee, Jun Ho, et al.
Publicado: (2021)

Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions
por: Cacabelos, Ramón, et al.
Publicado: (2021)

Alzheimer's and Parkinson's disease therapies in the clinic
por: Chopade, Puja, et al.
Publicado: (2022)

Metabolic Mechanisms Connecting Alzheimer’s and Parkinson’s Diseases: Potential Avenues for Novel Therapeutic Approaches
por: Colca, Jerry R., et al.
Publicado: (2022)

Association between Sleep, Alzheimer’s, and Parkinson’s Disease
por: Matsumoto, Sumire, et al.
Publicado: (2021)

The aging immune system in Alzheimer’s and Parkinson’s diseases
por: Heavener, Kelsey S., et al.
Publicado: (2022)

Common and Trace Metals in Alzheimer’s and Parkinson’s Diseases
por: Doroszkiewicz, Julia, et al.
Publicado: (2023)

Chalcones as Potential Ligands for the Treatment of Parkinson’s Disease
por: Królicka, Ewelina, et al.
Publicado: (2022)

Potential effects of cannabinoids on audiovestibular function: A narrative review
por: Guerra, Joaquin, et al.
Publicado: (2022)

New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases
por: Hölscher, Christian
Publicado: (2014)

The Vitamin D Receptor as a Potential Target for the Treatment of Age-Related Neurodegenerative Diseases Such as Alzheimer’s and Parkinson’s Diseases: A Narrative Review
por: Lasoń, Władysław, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ekt22q7sjs7fkmcsqtcch9858h